These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 36505471)
1. Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy. Zhang L; Shi Y; Han X Front Immunol; 2022; 13():1032221. PubMed ID: 36505471 [TBL] [Abstract][Full Text] [Related]
2. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664 [TBL] [Abstract][Full Text] [Related]
3. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? Duma N; Abdel-Ghani A; Yadav S; Hoversten KP; Reed CT; Sitek AN; Enninga EAL; Paludo J; Aguilera JV; Leventakos K; Lou Y; Kottschade LA; Dong H; Mansfield AS; Manochakian R; Adjei AA; Dronca RS Oncologist; 2019 Nov; 24(11):e1148-e1155. PubMed ID: 31036771 [TBL] [Abstract][Full Text] [Related]
13. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. Chuah S; Lee J; Song Y; Kim HD; Wasser M; Kaya NA; Bang K; Lee YJ; Jeon SH; Suthen S; A'Azman S; Gien G; Lim CJ; Chua C; Hazirah SN; Lee HK; Lim JQ; Lim TKH; Yeong J; Chen J; Shin EC; Albani S; Zhai W; Yoo C; Liu H; Choo SP; Tai D; Chew V J Hepatol; 2022 Sep; 77(3):683-694. PubMed ID: 35430299 [TBL] [Abstract][Full Text] [Related]
14. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061 [TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663 [TBL] [Abstract][Full Text] [Related]
16. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D Front Oncol; 2021; 11():749064. PubMed ID: 34900695 [TBL] [Abstract][Full Text] [Related]
17. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312 [TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma. van Duin IAJ; Schuiveling M; Ter Maat LS; Veta M; van Eijs MJM; Verheijden RJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; Hospers GAP; Labots M; de Groot JWB; Kapiteijn E; Piersma D; Vreugdenhil G; Westgeest H; Schrader AMR; van Diest PJ; Blokx WAM; Suijkerbuijk KPM Immunooncol Technol; 2024 Dec; 24():100714. PubMed ID: 39045171 [TBL] [Abstract][Full Text] [Related]
19. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials. Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182 [TBL] [Abstract][Full Text] [Related]
20. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]